Marketing: Page 5
-
Courtesy of Eisai
Leqembi voted down by European regulators
Eisai plans to appeal the EMA’s negative recommendation for the Alzheimer’s drug, hoping to break into a market analysts expect could eventually bring billions of dollars in sales.
By Jacob Bell • July 26, 2024 -
Permission granted by Boehringer Ingelheim
Boehringer cuts price of Humira biosimilar in bid to build use
The German drugmaker will offer a 92% discount on a copycat version of Humira for people who pay cash for the drug through GoodRx.
By Jonathan Gardner • July 18, 2024 -
Explore the Trendline➔
Brian Tucker / BioPharma Dive/BioPharma Dive
TrendlineCommercialization
New drugs for obesity and Alzheimer’s look set to become blockbusters, reshaping pharma marketing strategies just as many current top-sellers near looming patent cliffs.
By BioPharma Dive staff -
Douglas Cliff via Getty Images
As GLP-1 drugs boom, other healthcare companies are cashing in
With more Americans taking obesity medications, adjacent businesses are offering supportive services to offset side effects, collect data and document new health benefits.
By Amy Baxter • July 10, 2024 -
Courtesy of Amazon
Amazon expands drug subscription program to Medicare members
RxPass, which fills prescriptions for generic drugs, is now available to more than 50 million Medicare members after Amazon brought it into compliance with the insurance program’s regulatory standards.
By Rebecca Pifer • June 20, 2024 -
iStock / PRImageFactory
Sponsored by PhreesiaEarly patient engagement can improve medication adherence. Here’s how.
Research shows that 20% of patients have failed to fill a script in the past, and one-third aren’t confident managing their illness. Engaging patients as soon as a medicine is prescribed can help.
June 17, 2024 -
digicomphoto via Getty Images
New Alzheimer's drugsDonanemab approval would fuel growth of amyloid-blocking Alzheimer’s drugs, analysts say
After an FDA panel backed Lilly’s drug three weeks ago, Wall Street analysts noted how its clearance — now granted — could benefit Eisai and Biogen’s rival Leqembi.
By Jonathan Gardner • June 11, 2024 -
Riska via Getty Images
Sponsored by VMS BioMarketingOral cancer medications: The adherence paradox
The number of oral cancer medications is increasing, opening new possibilities for improved convenience, but some studies show much lower adherence rates with oral oncolytics.
By Abigail Mallon, Chief Patient Experience Officer, VMS BioMarketing • June 3, 2024 -
Permission granted by Akili Interactive
Digital therapeutics firm Akili to sell for $34M
Akili, which makes a video game treatment for ADHD, will merge with Virtual Therapeutics to create a larger digital health company.
By Elise Reuter • May 30, 2024 -
Mario Tama via Getty Images
Pfizer and Lilly are elbowing into the direct-to-consumer market. Will it work?
Direct-to-consumer platforms can offer consumers an online path to sourcing popular medications, but some therapeutic areas may be better suited for the business model.
By Amy Baxter • May 22, 2024 -
Courtesy of Eisai
New Alzheimer's drugsEisai sets new revenue target for Alzheimer’s drug Leqembi
The annual forecast, which comes as Eisai and Biogen have begun submitting a more convenient form of Leqembi for approval, looks “more realistic” than previous guidance, according to Jefferies analysts.
By Jacob Bell • May 15, 2024 -
Courtesy of AbbVie
Biosimilars are gaining ground. The IRA could push them further next year.
As commercial momentum builds, coverage incentives for the Medicare market are expected to favor biosimilars in 2025.
By Amy Baxter • May 13, 2024 -
Scott Olson via Getty Images
Novo sees Wegovy sales dip on lower price, tight supply
First quarter sales of the in-demand obesity drug were down slightly compared to the fourth quarter last year, as the company tries to meet demand.
By Jonathan Gardner • May 2, 2024 -
Mario Tama via Getty Images
Pfizer’s strong Vyndaqel sales draw attention to rare disease drug’s patent life
Sales of the transthyretin amyloidosis treatment widely beat Wall Street forecasts in the first quarter. The company aims to extend its patent exclusivity.
By Ned Pagliarulo • May 1, 2024 -
Jon Cherry via Getty Images
FDA defends lab test rule, as critics fear industry upheaval
The new policy aims to ensure important diagnostics remain available to patients, but some experts caution the increased regulatory burden could slow access to testing.
By Susan Kelly • April 30, 2024 -
deliormanli via Getty Images
FDA finalizes lab developed test rule over industry opposition
Risks associated with the tests have increased, requiring greater oversight to protect patients, the agency contends.
By Susan Kelly • April 29, 2024 -
Win McNamee via Getty Images
AbbVie tries to reassure investors on Humira biosimilar threat
Prescription volume erosion is tracking with company forecasts, executives claimed, even as more insurers could exclude the branded drug.
By Jonathan Gardner • April 26, 2024 -
Courtesy of Eisai
Biogen to invest more in launch of Alzheimer’s drug Leqembi
Growing demand has convinced Biogen that it's worth expanding the sales force around Leqembi by 30%.
By Jacob Bell • April 24, 2024 -
Brad Barket via Getty Images
23andMe CEO plans to take company private
Company head Anne Wojcicki is considering buying all outstanding shares of the DNA testing firm, which has seen its stock slump in recent years.
By Elise Reuter • April 18, 2024 -
Courtesy of Teva Pharmaceutical
Stelara biosimilar from Alvotech, Teva approved by FDA
The companies plan to launch their copycat version of the blockbuster immune disease drug early next year, per a legal settlement with J&J.
By Kristin Jensen • April 17, 2024 -
iStock via Getty Images
Roche reports survival data for new dual-acting lymphoma drug
The results could give Roche’s Columvi an edge over a rival medicine from AbbVie and Genmab, while Regeneron awaits an approval of its own therapy.
By Jonathan Gardner • April 15, 2024 -
Mario Tama via Getty Images
European regulator concludes no suicide link to obesity drugs
The decision clears a concern hanging over GLP-1 medicines like Ozempic since reports of suicidal ideation and self-harm among people taking the drugs surfaced in July.
By Jonathan Gardner • April 12, 2024 -
US sues Regeneron, alleging false price reporting on Eylea
The lawsuit claims the drugmaker didn’t disclose reimbursement to drug distributors for credit card fees, artificially inflating the reported price of the blockbuster eye drug.
By Kristin Jensen • April 11, 2024 -
Courtesy of Regeneron Pharmaceuticals
FDA rejects Regeneron lymphoma drug, setting back company’s oncology push
The agency wants Regeneron to make more progress with a confirmatory trial before clearing odronextamab, a “bispecific” antibody being developed for multiple blood cancers.
By Jonathan Gardner • March 25, 2024 -
shutterstock.com/VAlekStudio
Sponsored by VeevaGive HCPs a proactive way to reach your field team: Add inbound
HCPs today want inbound channels for help when they need it. See how you can meet their preferences.
By Paul Shawah, Executive Vice President of Strategy, Veeva • March 18, 2024 -
dkfielding via Getty Images
BIO changes stance, backs bill to limit China’s role in US biotech
Pressed by lawmakers, the lobbying group is also “taking steps” to end its relationship with WuXi-AppTec, a major contract manufacturer to the biopharmaceutical industry.
By Jonathan Gardner • March 14, 2024
Previous
